The kidneys as an emerging target for the treatment of diabetes mellitus: What we know, thought we knew and hope to gain

International Journal of Diabetes Mellitus

Volumn 2, Issue 2, 2010, Pages 125-126

  Ahmed, Mohamed H ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetes mellitus; Kidney; SGLT2

Indexed keywords

DAPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; GLUCOSE METABOLISM; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; KIDNEY; KIDNEY TUBULE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 77956656798     PISSN: 18775934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdm.2010.05.006     Document Type: Article

References (14)

1. J.E. Gerich, C. Meyer, H.J. Woerle, and M. Stumvoll Renal gluconeogenesis: its importance in human glucose homeostasis Diabetes Care 24 2 2001 382 391
2. I.S. Wood, and P. Trayhurn Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins Br J Nutr 89 1 2003 3 9
3. R. Santer, M. Kinner, C.L. Lassen, R. Schneppenheim, P. Eggert, and M. Bald Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 11 2003 2873 2882
4. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, and S.A. Biller Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 6 2008 1723 1729
5. Y. Fujimori, K. Katsuno, K. Ojima, I. Nakashima, S. Nakano, and Y. Ishikawa-Takemura Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats Eur J Pharmacol 609 1-3 2009 148 154
6. Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J Pharmacol Exp Ther 327 1 2008 268 276
7. A. Oku, K. Ueta, M. Nawano, K. Arakawa, T. Kano-Ishihara, and M. Matsumoto Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats Eur J Pharmacol 391 1-2 2000 183 192
8. B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, and L. Li Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 5 2009 520 526
9. B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 5 2009 513 519
10. J.F. List, V. Woo, E. Morales, W. Tang, and F.T. Fiedorek Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 4 2009 650 657
11. J.P. Wilding, P. Norwood, C. T'joen, A. Bastien, J.F. List, and F.T. Fiedorek A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 32 9 2009 1656 1662
12. D.E. Bonds, M.E. Miller, R.M. Bergenstal, J.B. Buse, R.P. Byington, and J.A. Cutler The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
13. M. Al-Arouj, R. Bouguerra, J. Buse, S. Hafez, M. Hassanein, and M.A. Ibrahim Recommendations for management of diabetes during Ramadan Diabetes Care 28 9 2005 2305 2311
14. I. Salti, E. Bénard, B. Detournay, M. Bianchi-Biscay, C. Le Brigand, and C. Voinet A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study Diabetes Care 27 10 2004 2306 2311